Deubiquitinating Enzymes in Parkinson’s Disease

Joy Chakraborty1 and Elena Ziviani2*

1 Department of Cell Biology and Physiology, CSIR-Indian Institute of Chemical Biology-TRUE Campus, Kolkata, India,
2 Department of Biology, University of Padova, Padua, Italy

Mitochondrial dysfunction and neurodegeneration have been directly correlated in many neurodegenerative disorders. Parkinson’s disease (PD) in particular has been extensively studied in this context because of its well-characterized association with mitophagy, a selective type of autophagy that degrades mitochondria. Mitophagy is triggered by ubiquitin modification of proteins residing on the surface of mitochondria. Therefore, mitophagy is subject to suppression by deubiquitination. In recent years, many deubiquitinase enzymes (DUBs) emerged as therapeutic targets to compensate hindered mitophagy in PD. It is reasonable that inhibition of specific DUBs should induce mitophagy by blocking deubiquitination of mitochondrial proteins, although the signaling pathway is not always that linear. The broad aspect suggests that there could be cross talks among DUBs, which may in turn have synergistic effect to rescue the disease progression. In this short review we have highlighted DUBs that hold therapeutic value in the field of neurodegenerative diseases, PD in particular.

Keywords: Parkinson’s disease, ubiquitination, DUBs, mitophagy, neurodegeneration

PARKINSON’S DISEASE AND MITOCHONDRIAL QUALITY CONTROL: NEW ANSWERS TO AN OLD RIDDLE

The age-old question: how to address and slow down Parkinson’s disease (PD) progression, still remains elusive. The progressive decline in neuro- motor behaviors, which originates from specific loss of dopaminergic neurons in Substantia Nigra Pars Compacta, is the major concern. Dopaminergic neurons are known to be more vulnerable than other cell types because of their reliance on a specific subtype of Ca2+ channels to maintain their autonomous pacemaking activity (Chan et al., 2007), and their high-energy demand to sustain dopamine metabolism (Michel and Hefti, 1990; Zecca et al., 2003; Greenamyre and Hastings, 2004). Albeit fundamental for ATP synthesis to fuel cell needs (Nunnari and Suomalainen, 2012), oxidative phosphorylation

Abbreviations: ATXN3, Ataxin-3; BNIP3L, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like; CCCP, carbonyl cyanide m-chlorophenyl hydrazone; CMA, chaperone-mediated autophagy; DUBs, deubiquitinase enzymes; FIS1, fission 1; FKBP8, FK506-binding protein 8; FUNDC1, FUN14 domain-containing protein 1; Gp78, glycoprotein 78; Hsp, heat shock protein; iPS, induced pluripotent stem cell; LAMP2, lysosome-associated membrane glycoprotein 2; LIR, LC3 interacting region; Map1lc3b, microtubule-associated proteins 1A/1B light chain 3B; MDV, mitochondrial-derived vesicle; MFN, Mitofusin; Miro1, mitochondrial Rho GTPase 1; MJD, Machado–Joseph disease; MFTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; MUL1, mitochondrial E3 ubiquitin protein ligase 1; Nix, NIP3-like protein X; PARK2, Parkinson disease protein 2; PD, Parkinson’s disease; PINK1, PTEN-induced kinase 1; ROS, reactive oxidative species; SIAH, seven in absentia homolog; SQSTM1, P62/sequestosome-1; TOM, translocase of outer membrane; UCH-L1, ubiquitin carboxy-terminal hydrolase isozyme L1; UPS, ubiquitin proteasome system; USP, ubiquitin-specific-processing protease; VDAC, voltage-dependent anion channel.
can generate reactive oxidative species (ROS), and mitochondria can become source of cellular toxicity. The relationship between PD and mitochondria is further advocated by the fact that people with mutation in genes which are known to control mitochondrial degradation, like PINK1 and Parkin (Narendra et al., 2008; Geisler et al., 2010; Matsuda et al., 2010; Vives-Bauza et al., 2010; Bayne and Tremppe, 2019; Biswas et al., 2020), develop a juvenile autosomal recessive form of PD (Kitada et al., 1998; Valente et al., 2004). The PINK1/Parkin pathway depicts that upon depolarisation of mitochondria, PINK1 recruits Parkin to mitochondria (Matsuda et al., 2010; Narendra D.P. et al., 2010; Vives-Bauza et al., 2010) to ubiquitinate specific proteins (VDAC, TOM20, MFN1, and MFN2, FIS1 among the most studied ones (Geisler et al., 2010; Tanaka et al., 2010; Ziviani et al., 2010; Chan et al., 2011; Yoshii et al., 2011; Sarraf et al., 2013; Junqueira et al., 2019). This event propels the organelle to the next step of mitophagy, if not pushed toward apoptosis (Ham et al., 2020). Ubiquitinated proteins on mitochondrial surface can directly interact with the autophagic isolation membrane via recruitment of autophagy receptors that contain conserved MAP1LC3/LC3-interacting regions (LIRs) (Johansen and Lamark, 2011). Several mitophagy receptors/adapters have been identified including p62/SQSTM1, FUNDC1, FKBP8, and BNIP3L/Nix, which are recruited to mitochondria under mitochondrial uncoupling stress conditions (Geisler et al., 2010; Narendra D. et al., 2010; Okatsu et al., 2010; Bhujabal et al., 2017), following hypoxia (Liu et al., 2012), or during activation of specific physiological pathways that control cell differentiation (Schweers et al., 2007; Sandoval et al., 2008; Novak et al., 2010). Not surprisingly, there are additional E3-ubiquitin ligases other than Parkin, which can ubiquitinate common targets on mitochondrial surface leading to Parkin-independent mitophagy. For example, MUL1 and Parkin share Mfn1 and two as common substrates, and they are both dependent on PINK1 for mitochondrial recruitment (Yun et al., 2014). Gp78 and Parkin also share common substrates, but whether Gp78 mitochondrial recruitment is PINK1 dependent or not is not fully clear (Fu et al., 2013). SIAH activation can trigger mitophagy independently of Parkin, but requires PINK1 to translocate to mitochondria (Szargel et al., 2016). Excavating these E3 ligases as alternatives to promote Parkin independent mitophagy is currently under intense investigation, and might hold therapeutic opportunities.

Many studies highlighted the importance of the ubiquitin proteasome system (UPS) for mitophagy execution (Yoshii et al., 2011). Proteosome-dependent degradation of mitochondrial pro-fusion proteins Mitofusins helps segregating dysfunctional mitochondrial from the mitochondrial network, and contributes to mitochondrial fission, which is required for efficient degradation (Tanaka et al., 2010). In addition, proteosome-dependent rapture of the outer mitochondrial membrane (Yoshii et al., 2011) exposes the inner mitochondrial membrane receptors of LC3, like Prohibitin two, (Wei et al., 2017) which prompt the formation of the autophagic isolation membrane.

It should be noted that there are other means by which mitochondrial quality control can be achieved that do not require the autophagy machinery. In particular, vesicles can bud from the mitochondrial network to deliver oxidized mitochondrial components to the lysosome for degradation (McLelland et al., 2014). These mitochondrial-derived vesicles (MDVs) represent a mechanism for selective removal of damaged mitochondrial parts, such as oxidized mitochondrial proteins, without degrading the entire organelle. An endosome-lysosome mitochondrial degradation pathway has also been recently described, in which damaged mitochondria are sequestered into early endosomes and delivered to lysosome for degradation (Hammerling et al., 2017). Both pathways are Parkin-dependent. Interestingly, canonical PINK1/Parkin pathway does not seem to be prevalent in neurons (Cai et al., 2012; Ashrafi et al., 2014; Lin et al., 2017). This raises the question whether neurons engage distinct mechanisms of mitochondrial quality control. Because neurons remain in non-dividing state, maintenance and recovery of mitochondrial integrity might be preferable to mitochondrial degradation (Puri et al., 2019).

In conclusion, different pathways are engaged to promote mitochondrial quality control. It is plausible that different cells deal with mitochondrial quality control differently, and the absence of one pathway and the level of compensation by the others may turn out to be the deciding factor for cell survival.

**DUBS AND MITOCHONDRIAL QUALITY CONTROL**

Because ubiquitination plays an important role in mitochondrial quality control, the current field of therapeutic excavation targets those candidates, which can increase mitochondrial ubiquitination. To preserve mitochondrial ubiquitination long enough to activate mitophagy, one compound should either be able to enhance mitochondrial ubiquitination or inhibit deubiquitination. The class of enzymes, which counteracts ubiquitin ligases are known as deubiquitinating enzymes (DUBs). The general notion states that there are three different ways by which DUBs can affect mitophagy: (i) by regulating the stability of Parkin, (ii) by antagonizing the activity of Parkin and finally (iii) by regulating the level of proteasome activity and autophagy (Table 1 and Figure 1). Thus, these parameters were used as read-out for large-scale or DUBs-specific genetic screening to identify potential novel regulators of mitophagy. Durcan et al. used CCCP-induced Parkin translocation and a DUBs- specific RNAi-based approach, to identify USP8 as an important controller of stress-induced Parkin translocation (Durcan et al., 2014). USP8 interacts with the epidermal growth factor receptor, and regulates proliferation and differentiation. It also controls endosomal trafficking by ubiquitin-mediated sorting of the endocytosed cargoes (Mizuno et al., 2005; Row et al., 2006; Williams and Urbe, 2007). It has been previously demonstrated that auto-ubiquitination inhibits Parkin activity and translocation to depolarised mitochondria (Wauer and Komander, 2013; Kumar et al., 2015; Seirafi et al., 2015). USP8 deubiquitinates the K6 linked ubiquitin conjugates from Parkin, and contributes to the release of the auto-inhibited state of Parkin, to promote CCCP-induced Parkin translocation and Parkin-dependent mitophagy (Durcan et al., 2014). In a similar
The association between ATXN3 mutation and dominantly inherited ataxia is well-established (Chakraborty et al., 2014). Deubiquitinating enzyme Ataxin-3 (ATXN3), which regulates proteasome and autophagy, has been shown to be protective against PD phenotypes in Drosophila models (Chakraborty et al., 2018). Importantly, USP14 inhibits mitophagy by antagonizing Parkin, although its role in this context is controversial (Lee et al., 2010). The USP14 trims the ubiquitin chains one at a time, increasing the dwelling time and degradation rate of proteasome-processed proteins. USP14 also inhibits proteasome and autophagy, which may explain some of the PD-related phenotypes in Machado–Joseph disease (Durcan et al., 2012).

DUBs-specific RNAi-based cell screening, and using Mfn steady state levels as read out, USP8 and USP14 were identified to affect pathologically elevated Mfn protein levels. USP8 genetic and pharmacological inhibition improved mitochondrial function, climbing ability, life span, and dopaminergic neurons loss of two Drosophila models of mitochondrial dysfunction (von Stockum et al., 2019). Interestingly, USP8 knockdown also protects from α-synuclein–induced locomotor deficits and cell loss in an α-synuclein Drosophila model of PD (Alexopoulos et al., 2016), further supporting the potential therapeutic implication of USP8 inhibition. USP14 is among the DUBs, which remain in close association with the proteasome complex, and affect the degradation rate of proteasome-processed proteins. USP14 trims the ubiquitin chains one at a time, increasing the dwelling time of the protein on the proteasome (Lee et al., 2010). Thus, USP14 inhibition enhances proteasome activity that was found to impact autophagy, although its role in this context is controversial (Xu et al., 2016; Kim et al., 2018). Importantly, USP14 genetic or chemical inhibition exacerbates basal mitophagy in PINK1/Parkin independent manner, and proved to be protective in two well-established Drosophila models of PD (Chakraborty et al., 2018). Deubiquitinating enzyme Ataxin-3 (ATXN3), which mutation is associated to dominantly inherited ataxia (known as Machado–Joseph disease or MJD), was also found to directly interact with Parkin, and influence its ubiquitination. The mutant form of ATXN3 was reported to increase Parkin turnover by promoting its degradation via autophagy (Durcan and Fon, 2011; Durcan et al., 2011). ATXN3 regulates Parkin auto-ubiquitination by stabilizing the complex between Parkin and its E2 ubiquitin-conjugating enzyme, thus impeding the efficient transfer of ubiquitin from the E2 ubiquitin-conjugating enzyme to Parkin (Durcan et al., 2012). Increased Parkin turnover caused by mutant ATXN3 might explain some of the PD-related phenotypes that are observed in MJD, although a direct association between PD and ATXN3 mutation is yet to be well characterized. In another study that screened Flag-tagged human DUB cDNA library for CCCP-induced mitophagy, authors identified USP30 that efficiently antagonized mitochondrial loss (measured by immunostaining for TOM20). The study showed that Parkin and USP30 have common targets such as TOM20 and MIRO1, which are ubiquitinated by Parkin during CCCP-mediated mitophagy. Interestingly, USP30 is actually a Parkin substrate, and Parkin-dependent ubiquitination of USP30 facilitates proteasome-dependent degradation of the protein so that this DUB is kept at low levels when active Parkin is required to promote mitophagy. Knockdown of USP30 rescues defective mitophagy caused by parkin mutations.
and, more interestingly, improves mitochondrial phenotype of PINK1 and Parkin KO flies (Bingol et al., 2014). Thus, enhanced proteasome activity helps mitophagy via enhanced degradation of Parkin-opposing DUB USP30. Analysis of Parkin interactome by tandem affinity purification coupled to mass spectrometry identified DUB USP15 as physical Parkin interactor, but only in overexpressed conditions. The mechanism of action of USP15 is demonstrated to be by antagonizing Parkin ubiquitination on common mitochondrial targets, like Mfn2, and does not affect Parkin translocation or ubiquitination levels. Downregulation of USP15 promotes mitophagy in primary fibroblasts generated from skin biopsy of patients with PARK2 mutation, and rescues mitochondrial as well as locomotor phenotype of parkin RNAi flies (Cornelissen et al., 2014). Importantly, USP15 downregulation enhances basal mitophagy in vivo in parkin-downregulated flies measured by mt-keima, and specifically in neuronal cells. Because mitophagy increases with aging in wild type flies, but not in PINK1 or Parkin KO flies, the effect of USP15 KD on basal mitophagy has been interpreted as the mechanism of rescue seen in flies (Cornelissen et al., 2018).

Among the regulators of autophagy and proteasome, another DUB UCH-L1 was found to be associated with PD. UCH-L1 acts on polyubiquitin chain, and increase availability of free monomeric ubiquitin to the ubiquitin proteasome system, thus increasing proteasome-dependent degradation. Interestingly, the I94M mutation in UCH-L1 has been found in autosomal dominant PD patients (Leroy et al., 1998; Kabuta et al., 2008), and reduced mRNA and protein levels of this DUB were found in PD post-mortem samples from frontal cortex and medulla oblongata. Because UCH-L1 influences the activity of the proteasome, and it is associated with pathological α-Synuclein accumulation, these results led to the conclusion that UCH-L1 contributes to abnormal protein aggregation (Barrachina et al., 2006). In perfect agreement with this, it was reported that UCH-L1 directly interacts with chaperone-mediated autophagy (CMA), by physically binding to LAMP-2A, Hsp70 and Hsp90 (Kabuta et al., 2008). It should be noted that a protective S18Y UCH-L1 variant has also reported to be reversely correlated to the disease onset (Carmine Belin et al., 2007), although contrasting works on this topic have been published (Healy et al., 2006). The protective feature of the mutation has been specifically studied in the dopaminergic system of MPTP induced mouse model of PD, and is attributed to its antioxidant property (Xilouri et al., 2012). Several lines of evidence indicate that DUB USP9X also plays a role in the etiology of PD, and other neurodegenerative diseases. USP9X is an ecletic DUB that is highly conserved from Drosophila to mammals. It plays a role in human cancer, developmental and autoimmune diseases. In the context of neurodegeneraiton, USP9X has been shown to direct the autophagic degradation of α-Synuclein by deubiquitinating its monoubiquitinated form (Rott et al., 2011). Interestingly, in brain tissue, USP9X colocalises with α-Synuclein inclusions, and PD patients present reduced levels of USP9X. It is believed that decreased levels of USP9X result in accumulation of monoubiquitinated α-Synuclein, which are more prone to aggregate and caused neuronal toxicity. Finally, DUB USP24 was recently identified as a negative regulator of autophagy by affecting steady state levels of autophagy factor ULK1. USP24 downregulation promotes ULK1 stability, increases the autophagic flux and prevents age-dependent neurite growth decline of an iPSCs-derived dopaminergic neuronal model (Thayer et al., 2020). Interestingly, USP24 genetic polymorphisms is correlated to PD onset (Li et al., 2006; Haugarvoll et al., 2009).

The potential involvement of these DUBs in mitochondrial autophagy has not been yet investigated.

**CONCLUSION**

The mammalian genome encodes for more than one hundred DUBs, indicative of large substrate specificity. The scenario depicts that there might be many overlapping pathways, which are controlled by multiple DUBs and may impact on PD development or progression. The cross talk between USP8, USP15, and ATXN3 can coordinate the activity of these DUBs, and ultimately control Parkin stability and activation (Figure 1). Interestingly, Parkin and USP30 have negative feedback loops on each other and might be very finely tuned under physiological conditions (Figure 1). As USP30 is a substrate of the proteasome, USP14 has the potential of controlling Parkin stability and Parkin-dependent mitophagy. Simultaneous studies to investigate the level and activity of these DUBs in PD models will be instrumental to further delineate the compensatory effects that might be crucial for the disease progression.

**AUTHOR CONTRIBUTIONS**

JC and EZ wrote the review.

**FUNDING**

Michael J. Fox Foundation for Parkinson’s Disease. Grant number 17247.

**REFERENCES**

Alexopoulou, Z., Lang, J., Perrett, R. M., Elschami, M., Hurry, M. E., Kim, H. T., et al. (2016). Deubiquitinase Usp8 regulates alpha-synuclein clearance and modifies its toxicity in Lewy body disease. *Proc. Natl. Acad. Sci. U.S.A.* 113, E4688–E4697. doi: 10.1073/pnas.1523597113

Ashrafi, G., Schlehe, J. S., LaVoie, M. J., and Schwarz, T. L. (2014). Mitophagy of damaged mitochondria occurs locally in distal neuronal axons and requires PINK1 and Parkin. *J. Cell Biol.* 206, 655–670. doi: 10.1083/jcb.201401070

Barrachina, M., Castano, E., Dalfo, E., Maes, T., Buesa, C., and Ferrer, I. (2006). Reduced ubiquitin C-terminal hydrolase-1 expression levels in dementia with Lewy bodies. *Neurobiol. Dis.* 22, 265–273. doi: 10.1016/j.nbd.2005.11.005
Hamley, D. G., Boule-Sleiman, P. M., Casas, J. P., Ahmadi, K. R., Lynch, T., Gandhi, S., et al. (2006). UCHL1 is not a Parkinson’s disease susceptibility gene. Ann. Neurol. 59, 627–633.

Johansen, T., and Lamark, T. (2011). Selective autophagy mediated by autophagic adapter proteins. Autophagy 7, 279–296. doi: 10.4161/auto.7.3.14487

Junqueira, S. C., Centeno, E. G. Z., Wilkinson, K. A., and Cimbronelli, H. (2019). Post-translational modifications of Parkinson’s disease-related proteins: phosphorylation, SUMOylation and Ubiquitination. Biochim. Biophys. Acta Mol. Basis. 1865, 2001–2007. doi: 10.1016/j.bbadis.2018.10.025

Kabuta, T., Furuta, A., Aoki, S., Furuta, K., and Wada, K. (2008). Aberrant interaction between Parkinson disease-associated mutant UCH-L1 and the lysosomal receptor for chaperone-mediated autophagy. J. Biol. Chem. 283, 23731–23738. doi: 10.1074/jbc.M801918200

Kim, E., Park, S., Lee, J. H., Mun, J. Y., Choi, W. H., Yun, Y., et al. (2018). Dual function of USP14 Deubiquitination in cellular proteasomal activity and autophagic flux. Cell Rep. 24, 732–743. doi: 10.1016/j.celrep.2018.06.058

Kitada, T., Asakawa, S., Hattori, N., Matsumine, Y., Yamamura, Y., Minoshima, S., et al. (1998). Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605–608. doi: 10.1038/33416

Kumar, A., Aguirre, J. D., Condos, T. E., Martinez-Torres, R. J., Chaugule, V. K., Toth, R., et al. (2015). Disruption of the autoinhibited state primes the E3 ligase parkin for activation and catalysis. EMBO J. 34, 2506–2521. doi: 10.15252/embj.201592337

Lee, B. H., Lee, M. J., Park, S., Oh, D. C., Elsasser, S., Chen, P. C., et al. (2010). Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179–184. doi: 10.1038/nature09299

Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Meezy, E., et al. (1998). The ubiquitin pathway in Parkinson’s disease. Nature 395, 451–452.

Li, Y., Schrodi, S., Rowland, C., Tacey, K., Catanese, J., and Grupe, A. (2006). Genetic evidence for ubiquitin-specific proteases USP24 and USP40 as candidate genes for late-onset Parkinson disease. Hum. Mutat. 27, 1017–1023. doi: 10.1002/humu.20382

Lin, M. Y., Cheng, X. T., Tammiminen, P., Xie, Y., Zhou, B., Cai, Q., et al. (2017). Reversing synaptphilin removes stressed mitochondria from axons independent of mitophagy under pathophysiological conditions. Neuron 94, 595–610.e6. doi: 10.1016/j.neuron.2017.04.004

Liu, L., Feng, D., Chen, G., Chen, M., Zheng, Q., Song, P., et al. (2012). Mitochondrial outer-membrane protein FUNDCl mediates hypoxia-induced mitophagy in mammalian cells. Nat. Cell Biol. 14, 177–185. doi: 10.1038/ncll2422

Matsuda, N., Sato, S., Shiba, K., Okatsu, K., Saihso, K., Gauthier, C., et al. (2010). PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J. Cell Biol. 189, 211–221. doi: 10.1083/jcb.200910146

McCallard, G. L., Souhannier, V., Chen, C. X., McBride, H. M., and Fon, E. A. (2014). Parkin and PINK1 function in a vesicular trafficking pathway regulating mitochondrial quality control. EMBO J. 33, 282–295. doi: 10.1002/embj.201385902

Michel, P. P., and Hefti, F. (1990). Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J. Neurosci. Res. 24, 732–743. doi: 10.1002/jnr.702428035

Mizuno, E., Iura, T., Mukai, A., Yoshimori, T., Kitamura, N., and Komada, M. (2005). Regulation of epidermal growth factor receptor down-regulation by UBPF-mediated deubiquitination at endosomes. Mol. Biol. Cell 16, 5163–5174. doi: 10.1091/mbc.e05-06-0560

Narendra, D., Kane, L. A., Hauser, D. N., Fearnley, I. M., and Youle, R. J. (2010). p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy 6, 289–295. doi: 10.4161/auto.6.8.13426

Narendra, D., Tanaka, A., Suen, D. F., and Youle, R. J. (2008). Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795–803. doi: 10.1083/jcb.200809125

Narendra, D. P., Jin, S. M., Tanaka, A., Suen, D. F., Gautier, C. A., Shen, J., et al. (2010). PINK1 is selectively stabilized on impaired mitochondria via Parkin-dependent mitophagy; VDAC1 is dispensable for both. Autophagy 6, 279–296. doi: 10.4161/auto.7.3.14487

Novak, I., Kirkin, V., McEwan, D. G., Zhang, J., Wild, P., Rozenkopn, A., et al. (2010). Nix is a selective autophagy receptor for mitochondrial clearance. EMBO Rep. 11, 45–51. doi: 10.1002/embor.2009.256
Nunnari, J., and Suomalainen, A. (2012). Mitochondria: in sickness and in health. 
Cell 148, 1145–1159. doi: 10.1016/j.cell.2012.02.035

Okatsu, K., Saito, K., Shimizu, M., Nakada, K., Shitara, H., Sou, Y. S., et al. (2010). p62/SQSTM1 cooperates with Parkin for perinuclear clustering of depolarized mitochondria. Genes Cells 15, 887–900. doi: 10.1111/j.1365-2443.2010.01426.x

Puri, R., Cheng, X. T., Lin, M. Y., Huang, N., and Sheng, Z. H. (2019). Mul1 restrains Parkin-mediated mitophagy in mature neurons by maintaining ER-mitochondrial contacts. Nat. Commun. 10:3645. doi: 10.1038/s41467-019-11365-5

Rott, R., Szargel, R., Haskin, J., Bandopadhayay, R., Lees, A. J., Shani, V., et al. (2011). alpha-Synuclein fate is determined by USP9X-regulated monoubiquitination. Proc. Natl. Acad. Sci. U.S.A. 108, 18666–18671. doi: 10.1073/pnas.1105725108

Row, P. E., Prior, I. A., McCullough, J., Clague, M. J., and Urbe, S. (2006). The ubiquitin isopeptidase UBPA regulates endosomal ubiquitin dynamics and is essential for receptor down-regulation. J. Biol. Chem. 281, 12618–12624. doi: 10.1074/jbc.M1165215200

Sandoval, H., Thiagarajan, P., Dasgupta, S. K., Schumacher, A., Prchal, J. T., Chen, M., et al. (2008). Essential role for Nix in autophagic maturation of erythroid cells. Nature 454, 232–235. doi: 10.1038/nature07006

Sarraf, S. A., Raman, M., Guarani-Pereira, V., Sowa, M. E., Huttlin, E. L., Gygi, S. P., et al. (2013). Landscape of the PARKIN-dependent ubiquitylome in response to mitochondrial depolarization. Nature 496, 372–376. doi: 10.1038/nature12043

Schweers, R. L., Zhang, J., Randall, M. S., Loyd, M. R., Li, W., Dorsey, F. C., et al. (2007). NIX is required for programmed mitochondrial clearance during reticulocyte maturation. Proc. Natl. Acad. Sci. U.S.A. 104, 19500–19505. doi: 10.1073/pnas.0708818104

Seifrai, M., Kozlov, G., and Gehring, K. (2015). Parkin structure and function. FEBS J. 282, 2076–2088. doi: 10.1111/febs.13249

Szargel, R., Shani, V., Abd Elghani, F., Mekies, L. N., Liani, E., Rott, R., et al. (2016). The PINK1, synphilin-1 and SIAH-1 complex constitutes a novel mitophagy pathway. Hum. Mol. Genet. 25, 3476–3490. doi: 10.1093/hmg/ddw189

Tanaka, A., Cleland, M. M., Xu, S., Narendran, D. P., Suen, D. F., Karbowski, M., et al. (2010). Proteasome and p97 mediate mitophagy and degradation of mitofusins induced by Parkin. J. Cell Biol. 191, 1367–1380. doi: 10.1083/jcb.201007013

Thayer, J. A., Awad, O., Hegedekar, N., Sarkar, C., Tesfay, H., Burt, C., et al. (2020). The PARK10 gene USP24 is a negative regulator of autophagy andULK1 protein stability. Autophagy 16, 140–153. doi: 10.1080/15548627.2019.1587574

Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Mucci, M. M., Harvey, K., Gispert, S., et al. (2004). Hereditary early-onset Parkinson’s disease caused by mutations in PINK1. Science 304, 1158–1160. doi: 10.1126/science.1096284

Vives-Bauza, C., Zhou, C., Huang, Y., Cui, M., de Vries, R. L., Kim, J., et al. (2010). PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc. Natl. Acad. Sci. U.S.A. 107, 378–383. doi: 10.1073/pnas.0911187107

Copyright © 2020 Chakraborty and Ziviani. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.